<DOC>
	<DOCNO>NCT00100893</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer forming , grow , come back . The use IH636 grape seed extract may prevent breast cancer . PURPOSE : This phase I trial study side effect best dose IH636 grape seed extract prevent breast cancer postmenopausal woman risk develop breast cancer .</brief_summary>
	<brief_title>IH636 Grape Seed Extract Preventing Breast Cancer Postmenopausal Women Risk Developing Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy IH636 grape seed proanthocyanidin extract , term suppression estrogen biosynthesis , healthy post-menopausal woman high risk develop breast cancer . - Determine safety tolerability dietary supplement , term symptom change marker bone lipid metabolism marker nonspecific adrenal suppression , participant . - Determine , preliminarily , optimum biologic dose dietary supplement , define suppression serum estradiol , participant . - Determine minimum duration use dietary supplement achieve aromatase inhibition participant . OUTLINE : This pilot , dose-finding , placebo-controlled study . Participants receive oral placebo twice daily day -14 0 . Participants receive oral IH636 grape seed proanthocyanidin extract twice daily day 1-85 . Treatment continue absence toxicity . Cohorts 6 participant receive one four dose level IH636 grape seed proanthocyanidin extract establish safe dose . PROJECTED ACCRUAL : A total 24 participant accrue study within 12 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Grape Seed Extract</mesh_term>
	<mesh_term>Proanthocyanidin</mesh_term>
	<mesh_term>Procyanidin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At risk develop breast cancer No history breast cancer ductal carcinoma situ PATIENT CHARACTERISTICS : Age 40 75 Sex Female Menopausal status Postmenopausal , define 1 follow criterion : No spontaneous menses ≥ 12 month Prior bilateral oophorectomy Prior hysterectomy folliclestimulating hormone within menopausal range Performance status ECOG 01 Life expectancy Not specify Hematopoietic Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 100,000/mm^3 WBC ≥ 3,500/mm^3 Absolute granulocyte count ≥ 1,500/mm^3 No coagulation disorder Hepatic SGOT SGPT ≤ 2 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Renal Creatinine ≤ 1.5 time ULN Cardiovascular No major illness cardiovascular system Pulmonary No major illness respiratory system Other No history invasive cancer within past 5 year except squamous cell basal cell skin cancer No major systemic infection No Cushing 's syndrome adrenal insufficiency No osteoporosis , define bone mineral density Tscore ≥ 2.5 dualenergy xray absorptiometry scan ( calcium and/or cholecalciferol [ vitamin D ] supplementation AND/OR bisphosphonate therapy allow provide participant stable dose study participation ) PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy More 3 month since prior hormonemodifying medication , include follow : Oral contraceptive Hormone replacement therapy Selective estrogen receptor modifier Aromatase inhibitor Gonadotropinreleasing hormone modifier Concurrent dehydroepiandrosterone ( DHEA ) allow , provide dose remains constant study participation Radiotherapy Not specify Surgery Not specify Other No red wine , red grape , white button mushroom directly study treatment White seedless grape allow No concurrent therapy</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>breast cancer</keyword>
</DOC>